Dr. Clay B Siegall co-founded Seattle Genetics, Inc. in 1997 where he has been acting as the chief executive officer since November 2000, and also as the president since June 2000. Talking about cancer research and therapeutic drug development, Dr. Siegall has almost 20 years of experience. He served as the Chief Scientific Officer from December 1997 to November 2002 and also as the executive vice-president of Seattle Genetics Inc. from December 1997 to June 2000.
He was a senior research investigator at Pharmaceutical Research Institute, which is a nonprofit independent development and research institute from February 1991 to January 1995. He also served as an interim chairman of Seattle Genetics Inc., a company which focuses on developing and commercializing monoclonal cancer treatment therapies since April 2004.
He also worked with Ultragenyx Pharmaceutical Inc., which focuses on treatment of rare and ultra-rare diseases since Jan 2014, as the director. He is sits on the board of governors in Fred Hutchinson Cancer Research Business Alliance as well as on the board of directors of Washington Biotechnology and Biomedical Association. He holds nine patents and also has 67 authorized scientific papers.
He was both a biotechnologist and a staff fellow at the National Cancer Institute and National Institute of Health. He is among the members of the Board of Scientific Counselors for Cancer Treatment Research Foundation, and also serves as the chief editor on the editorial board of three scientific journals. He won the Pierce Award in 1995 for his significant efforts in targeted toxins field. On January 2013, he worked as a non-executive director or miRNA Therapeutics, Inc., which is a company focused on microRNA-based oncology therapeutics till January 2017.
He received the Ernst and Young Pacific Northwest entrepreneur of the year award, as an award finalist in the category of healthcare. Dr siegall acquired his Ph.D. in genetics from George Washington University and also a BSc in Zoology from the University of Maryland.